Bausch Health (BHC)
(Delayed Data from NYSE)
$9.38 USD
+0.18 (1.96%)
Updated Mar 18, 2024 04:00 PM ET
After-Market: $9.40 +0.02 (0.21%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.38 USD
+0.18 (1.96%)
Updated Mar 18, 2024 04:00 PM ET
After-Market: $9.40 +0.02 (0.21%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Zacks News
UnitedHealth (UNH) Unit Makes Insulin More Affordable to Avail
by Zacks Equity Research
UnitedHealth Group's (UNH) sub-unit, Optum Rx, resorts to product shift within its formulary and makes the vital medication of insulin cost-effective, thereby boosting patients' access to it.
Bausch (BHC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Bausch (BHC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
TEVA Q3 Earnings In Line, Sales Beat, Revenue View Raised
by Zacks Equity Research
TEVA reports decent third-quarter results. The company raises its revenue guidance for 2023 for the second time this year while keeping the EPS range intact.
Bausch Health (BHC) Q3 Earnings & Sales Beat, '23 View Updated
by Zacks Equity Research
Bausch (BHC) surpasses third-quarter earnings and sales estimates as most of the business units post growth.
Bausch (BHC) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Bausch (BHC) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Bausch Health (BHC) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Bausch (BHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Bausch (BHC): Can Its 8.0% Jump Turn into More Strength?
by Zacks Equity Research
Bausch (BHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aurinia Pharmaceuticals (AUPH) and Bausch Health (BHC) have performed compared to their sector so far this year.
TEVA to Pay $225 Million to Settle Price-Fixing Charges (Revised)
by Zacks Equity Research
TEVA agrees to pay a fine of $225 million over five years per a DPA. Out of this amount, $22.5 million will be due each year from 2024 through 2027 and $135 million will become due in 2028.
TEVA to Pay $250 Million to Settle Price-Fixing Charges
by Zacks Equity Research
TEVA agrees to pay a fine of $225 million over five years per a DPA. Out of this amount, $22.5 million will be due each year from 2024 through 2027 and $135 million will become due in 2028.
New Strong Buy Stocks for August 18th
by Zacks Equity Research
APP, MELI, MBWM, SHG and BHC have been added to the Zacks Rank #1 (Strong Buy) List on August 18, 2023.
Best Value Stocks to Buy for August 15th
by Zacks Equity Research
BHC, FBIZ and KB made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 15, 2023.
3 Top-Ranked Value Stocks to Buy as Recession Worries Loom
by Zacks Equity Research
Invest in companies like BHC, LSEA and TNK, which carry a low price-to-earnings ratio compared to the S&P 500 amid fresh recession worries.
Best Momentum Stock to Buy for August 8th
by Zacks Equity Research
ACLS, BHC and JHX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 8, 2023.
Best Value Stocks to Buy for August 8th
by Zacks Equity Research
BHC, GPI and UPBD made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 8, 2023.
New Strong Buy Stocks for August 8th
by Zacks Equity Research
ISNPY, SWDBY, MKL, GPI and BHC have been added to the Zacks Rank #1 (Strong Buy) List on August 8, 2023.
Bausch Health's (BHC) Q2 Earnings & Sales Beat, '23 View Raised
by Zacks Equity Research
Bausch's (BHC) second-quarter earnings and sales surpass estimates. The company increases its revenue guidance for 2023.
Bausch (BHC) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Bausch Health (BHC) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of 8% and 6.03%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Bausch Health (BHC) Secures $600M Financing Facility, Stock Up
by Zacks Equity Research
Bausch (BHC) enters into a $600 million non-recourse financing facility with KKR to boost liquidity.
Bausch (BHC) Down on Tentative Approval to Xifaxan ANDA
by Zacks Equity Research
Bausch (BHC) declines after the FDA grants tentative approval to Norwichs ANDA for a generic version of Xifaxan.
Bausch (BHC) Gains on Court Ruling for Xifaxan Against Norwich
by Zacks Equity Research
Bausch (BHC) obtains a positive ruling for one of its top drugs, Xifaxan, against Norwich from the U.S. District Court of Delaware. Stock up in response to the same.
Bausch Health's (BHC) Q1 Earnings & Sales Miss, Shares Down
by Zacks Equity Research
Bausch (BHC) declines as it misses on earnings and sales in the first quarter.
Bausch (BHC) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Bausch (BHC) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Bausch Health (BHC) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Bausch (BHC) delivered earnings and revenue surprises of -30.67% and 0.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?